Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 (0) 1494 818026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Recruitment Consultant
laura@zenopa.com
+44 (0) 1494 818026

Testimonials
Zenopa was extremely effective during my search for a new sales role. I was very pleased with the types of job role put forward and the consistent number of opportunities that my account manager conti...
Nina, 2013

Roche's Zelboraf launches in UK

15 March 2012 00:00 in Pharmaceutical Company Product News


Roche's new personalised skin cancer therapy Zelboraf has been made available to patients across the UK.

The vemurafenib therapy has been licensed by European regulators for adult patients with specific BRAF gene mutations whose cancer is inoperable or has spread.

Data from a clinical study carried out by the Institute of Cancer Research has shown that Zelboraf is able to deliver significant increases in survival rates compared to standard chemotherapy, making it the first targeted therapy to do so in this indication.

The drug is designed for use in conjunction with Roche's cobas 4800 BRAF V600 Mutation Test, which will allow doctors to identify which patients can benefit from the treatment.

Currently, 10,000 people are diagnosed with malignant melanoma in the UK annually, with the increasingly prevalent disease causing 2,300 deaths a year.

Professor Alan Ashworth, chief executive of the ICR, said: "Advanced melanoma is a devastating disease and new treatments are desperately needed, so it's especially pleasing that patients will now be able to benefit from a drug that we helped develop."ADNFCR-8000103-ID-801318340-ADNFCR

Other news stories from 15/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd